PEPG
What one share of Pepgen holds
Pharmaceutical Preparations
PepGen Inc. (also referred to as “PepGen,” “we,” “our” or “us”) is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.
Pepgen’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.19 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.15 |
| Cash and investments | $1.69 |
| Book value | $1.73 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$30.27 | $0.55 | −$25.63 | — | −$33.29 |
| 2022 | — | −$4.42 | $0.24 | −$4.03 | — | $7.58 |
| 2023 | — | −$3.30 | $0.11 | −$3.01 | — | $4.55 |
| 2024 | — | −$2.85 | $0.02 | −$2.62 | — | $3.64 |
| 2025 | — | −$2.12 | $0.01 | −$1.94 | — | $2.14 |